.png)
Introduction
SAN FRANCISCO — Today, Unite Genomics announced a new partnership with a top 10 pharmaceutical company, adding to its growing list of pharma customers. The collaboration will empower Psoriasis patients to better navigate their care based on personalized insights from their own medical records.
.png)
The pharmaceutical company will integrate Unite’s technology directly into their patient engagement efforts. By analyzing medical data and physician notes (with patient consent), Unite will better understand patient needs and provide more tailored insights to support their treatment journey.
The solution is part of Unite's “Clinical Listening” offering. It leverages integrations into health systems and a direct relationship with each patient, to engage patients and physicians at pivotal moments in the care journey.
“We created Unite to help close gaps in care and improve the healthcare system as a whole. We’re excited to expand its use to psoriasis, a disease with significant treatment challenges and complex patient journeys, through this partnership,” said Taner Dagdelen, founder and CEO of Unite.
About
Unite is a health analytics and personalized engagement platform developed by pioneers in Artificial Intelligence (AI) from the University of California, Berkeley. It uses data from electronic medical records (EMR), a direct relationship with patients, and world class AI systems to understand where each patient is in their journey and unlock optimal care pathways. Unite’s platform connects to over 19,000 health systems in the U.S., giving it the unique ability to leverage real-time data flows for over 95% of patients across the country.
.png)